- ICH GCP
- Registre des essais cliniques de l'UE
Derniers essais
EudraCT Number: 2022-003594-33 | Sponsor Protocol Number: EORTC-1984-BCG | Start Date: 2023-06-16 | |||||||||||
Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE) | |||||||||||||
Medical condition: Triple negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002234-14 | Sponsor Protocol Number: OR2805-101 | Start Date: 2023-06-07 | ||||||
Sponsor Name: OncoResponse, Inc. | ||||||||
Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies | ||||||||
Medical condition: Solid tumor cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: ES (Ongoing) FR (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003467-21 | Sponsor Protocol Number: AROMUC5AC-1001 | Start Date: 2023-06-07 | |||||||||||
Sponsor Name: Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001403-33 | Sponsor Protocol Number: TCTLR-101 | Start Date: 2023-06-06 | ||||||||||||||||||||||||||
Sponsor Name: Ascendis Pharma Oncology Division A/S | ||||||||||||||||||||||||||||
Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor... | ||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumor malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000690-73 | Sponsor Protocol Number: BAY86-5321/21912 | Start Date: 2023-06-06 | |||||||||||
Sponsor Name: Bayer AG | |||||||||||||
Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi... | |||||||||||||
Medical condition: Neovascular (wet) age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000054-28 | Sponsor Protocol Number: OLIGOTREAT | Start Date: 2023-06-02 | |||||||||||
Sponsor Name: Klinikum der Universität München | |||||||||||||
Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003474-31 | Sponsor Protocol Number: COAV101B12301 | Start Date: 2023-06-01 | |||||||||||
Sponsor Name: Novartis Pharma AG | |||||||||||||
Full Title: A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002292-11 | Sponsor Protocol Number: VX20-880-101 | Start Date: 2023-06-01 | ||||||||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | ||||||||||||||||||
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia | ||||||||||||||||||
Medical condition: Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Temporarily Halted) NO (Temporarily Halted) NL (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002679-12 | Sponsor Protocol Number: EOCRC1-22 | Start Date: 2023-06-01 | ||||||||||||||||||||||||||
Sponsor Name: Enterome SA | ||||||||||||||||||||||||||||
Full Title: A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of c... | ||||||||||||||||||||||||||||
Medical condition: Patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy . | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003792-41 | Sponsor Protocol Number: DAROTAXEL | Start Date: 2023-05-26 | ||||||
Sponsor Name: Erasmus MC | ||||||||
Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer. | ||||||||
Medical condition: metastatic castration-resistant prostate cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |